Send to:

Choose Destination
See comment in PubMed Commons below
J Cell Biochem. 2006 Feb 1;97(2):226-32.

Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.

Author information

  • 1Department of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York 14642, USA.


Focal bone loss around inflamed joints in patients with autoimmune disease, such as rheumatoid arthritis, remains a serious clinical problem. The recent elucidation of the RANK/RANK-ligand/OPG pathway and its role as the final effector of osteoclastogenesis and bone resorption has brought a tremendous understanding of the pathophysiology of inflammatory bone loss, and has heightened expectation of a novel intervention. Here, we review the etiology of inflammatory bone loss, the RANK/RANK-ligand/OPG pathway, and the clinical development of anti-RANK-ligand therapy.

Copyright 2005 Wiley-Liss, Inc.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Write to the Help Desk